Effects of Evolocumab on Vitamin E and Steroid Hormone Levels: Results From the 52-Week, Phase 3, Double-Blind, Randomized, Placebo-Controlled DESCARTES Study.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Circulation Research

• Publication date

  2015-07-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/CIRCRESAHA.115.307071PMID 26228031
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Lipid-lowering efficacy of rosuvastatin.

  2017cited by this paper
• Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

  2015cited by this paper
• PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels.

  2015cited by this paper
• Ezetimibe added to statin therapy after acute coronary syndromes

  2015cited by this paper
• Abetalipoproteinemia and homozygous hypobetalipoproteinemia: a framework for diagnosis and management

  2014cited by this paper
• Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia: 52-Week Results From the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) Randomized Trial

  2014cited by this paper
• The Effect of Aggressive Rosuvastatin Treatment on Steroid Hormone Production in Men with Coronary Artery Disease

  2014cited by this paper
• A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.

  2014cited by this paper
• Cortisol: ACTH ratio to test for primary hypoadrenalism: a pilot study

  2013influential reference
• High density lipoprotein as a source of cholesterol for adrenal steroidogenesis: a study in individuals with low plasma HDL-C

  2013cited by this paper
• Chronic adrenal failure and hypergonadotropic hypogonadism in a patient with abetalipoproteinemia.

  2012cited by this paper
• The PCSK9 decade

  2012cited by this paper
• Ataxia with vitamin E deficiency and abetalipoproteinemia.

  2012cited by this paper
• Inhibition of pre-protein convertase serine kexin-9 (PCSK-9) as a treatment for hyperlipidaemia

  2012cited by this paper
• Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

  2011cited by this paper
• Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

  2010cited by this paper
• The Effects of Rosuvastatin on the Serum Cortisol, Serum Lipid, and Serum Mevalonic Acid Levels in the Healthy Indian Male Population

  2010cited by this paper
• Cellular cholesterol delivery, intracellular processing and utilization for biosynthesis of steroid hormones

  2010cited by this paper
• A multi-center, open label, crossover designed prospective study evaluating the effects of lipid lowering treatment on steroid synthesis in patients with Type 2 diabetes (MODEST Study)

  2009cited by this paper
• The measurement and importance of red cell survival

  2009cited by this paper
• Statins enhance circulating vitamin E.

  2008cited by this paper
• Effect of very low LDL-cholesterol on cortisol synthesis

  2008cited by this paper
• The LDL receptor is not necessary for acute adrenal steroidogenesis in mouse adrenocortical cells.

  2007cited by this paper
• Effects of simvastatin on plasma antioxidant status and vitamins in hypercholesterolemic patients.

  2007cited by this paper
• Abstract 340: The C679X Mutation in PCSK9 is Present and Lowers Blood Cholesterol in a Southern African Population

  2006influential reference
• Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote.

  2006influential reference
• Effects of combined administration of low dose atorvastatin and vitamin E on inflammatory markers and endothelial function in patients with heart failure

  2005cited by this paper
• Vitamin E: absorption, plasma transport and cell uptake

  2005cited by this paper
• Does statin therapy influence steroid hormone synthesis?

  2004cited by this paper
• Hormonal changes with cholesterol reduction: a double‐blind pilot study

  2004cited by this paper
• Endocrine function in abetalipoproteinemia: a study of a female patient of Greek origin.

  2004cited by this paper
• Atorvastatin treatment does not affect gonadal and adrenal hormones in type 2 diabetes patients with mild to moderate hypercholesterolemia.

  2003cited by this paper
• Measurement of lipid-soluble vitamins--further adjustment needed?

  2000cited by this paper
• Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia.

  2000cited by this paper
• Effects of long-term pravastatin treatment on spermatogenesis and on adrenal and testicular steroidogenesis in male hypercholesterolemic patients

  1998cited by this paper
• Effect of decreased plasma low-density lipoprotein levels on adrenal and testicular function in man.

  1997cited by this paper
• Sustained therapy with 3-hydroxy-3-methylglutaryl-coenzyme-A reductase inhibitors does not impair steroidogenesis by adrenals and gonads.

  1995cited by this paper
• Role of the low density lipoprotein receptor in the flux of cholesterol through the plasma and across the tissues of the mouse.

  1995cited by this paper
• Comparison of Vitamin E Levels in Human Plasma, Red Blood Cells, and Platelets Following Varying Intakes of Vitamin E

  1992cited by this paper
• Long-term therapy with high-dose simvastatin does not affect adrenocortical and gonadal hormones in hypercholesterolemic patients.

  1992cited by this paper
• The influence of simvastatin on adrenal corticosteroid production and urinary mevalonate during adrenocorticotropin stimulation in patients with heterozygous familial hypercholesterolemia.

  1991cited by this paper
• Effects of pravastatin and cholestyramine on gonadal and adrenal steroid production in familial hypercholesterolaemia.

  1991cited by this paper
• Influence of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, pravastatin, on corticosteroid metabolism in patients with heterozygous familial hypercholesterolemia.

  1991cited by this paper
• Cortisol secretion in patients on simvastatin.

  1990cited by this paper
• Adrenocortical function in patients on simvastatin.

  1990cited by this paper
• FK-506 and haemolytic uraemic syndrome.

  1990cited by this paper
• Cortisol secretion in patients on simvastatin.

  1990cited by this paper
• Plasma Cortisol and Testosterone in Hypercholesterolaemia Treated with Clofibrate and Lovastatin

  1989cited by this paper
• EFFECTS OF INHIBITION OF CHOLESTEROL SYNTHESIS BY SIMVASTATIN ON THE PRODUCTION OF ADRENOCORTICAL STEROID HORMONES AND ACTH

  1989cited by this paper
• Vitamin E and relationships among tocopherols in human plasma, platelets, lymphocytes, and red blood cells.

  1988cited by this paper
• Testicular function in type II hyperlipoproteinemic patients treated with lovastatin (mevinolin) or neomycin.

  1987cited by this paper
• The effect of mevinolin on steroidogenesis in patients with defects in the low density lipoprotein receptor pathway.

  1987cited by this paper
• The Use of Different Lipids to Express Serum Tocopherol: Lipid Ratios for the Measurement of Vitamin E Status

  1986cited by this paper
• The influence of mevinolin on the adrenal cortical response to corticotropin in heterozygous familial hypercholesterolemia.

  1985cited by this paper
• Blocking 3-hydroxy-3-methylglutaryl coenzyme A reductase with ML-236B enhances the plasma cortisol response to adrenocorticotropin in patients with hypercholesterolemia.

  1984cited by this paper
• Adrenal cortical function in homozygous familial hypercholesterolemia.

  1983cited by this paper
• Adrenal function in heterozygous and homozygous hypobetalipoproteinemia.

  1982cited by this paper
• Corticosteroid production in abetalipoproteinemia: evidence for an impaired response ACTH.

  1982cited by this paper

• Pushing the Limits of LDL Cholesterol: Emerging Paradigms in Cardiovascular Risk Reduction.

  2025cites this paper
• Prognostic Value of PCSK9 Levels in Premenopausal Women at Risk of Breast Cancer—Evidence from a 17-Year Follow-Up Study

  2024cites this paper
• PCSK9 in metabolism and diseases.

  2024cites this paper
• Genetics, Safety, Cost-Effectiveness, and Accessibility of Injectable Lipid-Lowering Agents: A Narrative Review

  2023cites this paper
• Immunometabolic Markers in a Small Patient Cohort Undergoing Immunotherapy

  2022cites this paper
• Safety of PCSK9 inhibitors.

  2022cites this paper
• Efficacy and Safety of an Investigational Single-Course CRISPR Base-Editing Therapy Targeting PCSK9 in Nonhuman Primate and Mouse Models

  2022cites this paper
• The role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in the pathophysiology of psoriasis and systemic lupus erythematosus

  2022cites this paper
• Insight into the Evolving Role of PCSK9

  2022cites this paper
• PCSK9 immunization using nanoliposomes: preventive efficacy against hypercholesterolemia and atherosclerosis

  2021cites this paper
• Pleiotropic Effects of PCSK-9 Inhibitors

  2021cites this paper
• The Effect of the PCSK9 Inhibitor Evolocumab on Aldosterone Secretion among High Cardiovascular Risk Patients: A Pilot Study

  2021cites this paper
• [Real-life efficacy and safety of PCSK9 inhibitors treatment: Experience in three hospitals in Asturias].

  2021cites this paper
• Reduced adrenal stress response in patients on PCSK9 inhibitor therapy.

  2021cites this paper
• Preclinical discovery and development of evolocumab for the treatment of hypercholesterolemia

  2020cites this paper
• CPAA_A_288831 191..202

  2020influential citation
• How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors.

  2020cites this paper
• Safety and Tolerability of PCSK9 Inhibitors: Current Insights

  2020cites this paper
• Proprotein convertase subtilisin/kexin type 9 in the dyslipidaemia of patients with axial spondyloarthritis is related to disease activity.

  2020cites this paper
• Cardiovascular and Metabolic Protection by Vitamin E: A Matter of Treatment Strategy?

  2020cites this paper
• Adverse events to PCSK-9 inhibitors: what is the current evidence?

  2020cites this paper
• Efficacy and safety of PCSK9 monoclonal antibodies: an evidence-based review and update

  2020cites this paper
• PCSK9 Monoclonal Antibodies: An Overview

  2020cites this paper
• Effects of evolocumab therapy and low LDL‐C levels on vitamin E and steroid hormones in Chinese and global patients with type 2 diabetes

  2020cites this paper
• PCSK9 Inhibitors: From Nature's Lessons to Clinical Utility.

  2020cites this paper
• PCSK9 inhibitors for treating hypercholesterolemia

  2020cites this paper
• Efficacy and safety of PCSK9 monoclonal antibodies

  2019cites this paper
• Cholesterol-Lowering Agents.

  2019influential citation
• How Low to Go With Lipid‐Lowering Therapies in a Cost‐effective and Prudent Manner

  2019cites this paper
• PCSK9 Inhibitors: Clinical Relevance, Molecular Mechanisms, and Safety in Clinical Practice

  2019cites this paper
• Safety and tolerability of injectable lipid-lowering drugs: an update of clinical data

  2019cites this paper
• Low Density Lipoprotein (LDL) Cholesterol as a Causal Role for Atherosclerotic Disease: Potential Role of PCSK9 Inhibitors

  2019cites this paper
• PCSK9 Inhibition: New Treatment Options and Perspectives to Lower Atherogenic Lipoprotein Particles and Cardiovascular Risk

  2019cites this paper
• Response to: ‘Association between osteoporosis and statins therapy’ by Lai

  2019cites this paper
• Short- and long-term effects of lipoprotein apheresis on plasma hormones in patients with therapy-resistant dyslipidemia.

  2019cites this paper
• A safety evaluation of evolocumab

  2018cites this paper
• Population pharmacokinetics and exposure–response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia

  2018cites this paper
• PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDLCholesterol.

  2018cites this paper
• Role of PCSK9 in lipid metabolism and atherosclerosis.

  2018cites this paper
• Why is hypercholesterolaemia so prevalent? A view from evolutionary medicine.

  2018cites this paper
• Cardiovascular Outcomes of PCSK9 Inhibitors: With Special Emphasis on Its Effect beyond LDL-Cholesterol Lowering

  2018cites this paper
• Clinical and pathophysiological evidence supporting the safety of extremely low LDL levels-The zero-LDL hypothesis.

  2018cites this paper
• Evolocumab: Considerations for the Management of Hyperlipidemia

  2018cites this paper
• Impact d'interventions non pharmacologiques sur les biomarqueurs émergents du risque cardiovasculaire : fonctionnalité des HDL et PCSK9

  2018cites this paper
• Adverse Events Associated With PCSK9 Inhibitors: A Real‐World Experience

  2018cites this paper
• The Evolving Future of PCSK9 Inhibitors.

  2018cites this paper
• Inhibiting PCSK9 — biology beyond LDL control

  2018cites this paper
• Is lower low-density lipoprotein cholesterol associated with lower androgen and erectile dysfunction in men?

  2018cites this paper
• PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review

  2018cites this paper
• Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism

  2018cites this paper
• Vascular Oxidative Stress: Impact and Therapeutic Approaches

  2018cites this paper
• Persistent Safety and Efficacy of Evolocumab in Patients with Statin Intolerance: a Subset Analysis of the OSLER Open-Label Extension Studies

  2018cites this paper
• PCSK9 inhibitors – from discovery of a single mutation to a groundbreaking therapy of lipid disorders in one decade

  2017cites this paper
• Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context

  2017cites this paper
• Anti-PCSK9 Antibodies: A New Era in the Treatment of Dyslipidemia.

  2017cites this paper
• PCSK-9: papel en las hipercolesterolemias y anticuerpos monoclonales específicos inhibitorios

  2017cites this paper
• The revolution in cholesterol management : putting PCSK 9 Inhibitors into practice

  2017cites this paper
• Targeting pro-protein convertase subtilisin kexin-9 as a novel therapy of hypercholesterolemia

  2017cites this paper
• Tachykinin neurokinin 3 receptor antagonists: a new treatment for cardiovascular disease?

  2017cites this paper
• PCSK9 Inhibitors: Treating the Right Patients in Daily Practice

  2017cites this paper
• Proprotein convertase subtilisin/kexin 9 inhibition in patients with familial hypercholesterolemia: Initial clinical experience.

  2017cites this paper
• The efficacy of anti-PCSK9 antibodies: Results from recent trials.

  2017cites this paper
• Can LDL cholesterol be too low? Possible risks of extremely low levels

  2017cites this paper
• Clinical utility of evolocumab in the management of hyperlipidemia: patient selection and follow-up

  2017cites this paper
• Evidence-based goals in LDL-C reduction

  2017cites this paper
• Retargeting the management of hypercholesterolemia – focus on evolocumab

  2016cites this paper
• Managing the lipid profile of coronary heart disease patients

  2016cites this paper
• Evolocumab: A Review in Hyperlipidemia

  2016cites this paper
• [Lipid-Lowering Therapy: a Look Into the Past and Prospects For the Near Future].

  2016cites this paper
• The Year in Cardiology 2015: Prevention

  2016cites this paper
• Unmet Needs in LDL-C Lowering: When Statins Won’t Do!

  2016cites this paper
• Determining When to Add Nonstatin Therapy: A Quantitative Approach.

  2016cites this paper
• Circulation Research "In This Issue" Anthology.

  2016cites this paper
• LDL-Cholesterol: Standards of Treatment 2016: A German Perspective

  2016cites this paper
• Einführung der PCSK9-Inhibitoren

  2016cites this paper
• Evolocumab for the treatment of homozygous familial hypercholesterolaemia

  2016cites this paper
• PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab

  2016cites this paper
• Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement.

  2016cites this paper
• Proprotein convertase subtilisin kexin type 9 inhibitors: update from clinical trials to real-world experience

  2016cites this paper
• Cardiac Exosome Modeling and Therapy ( p 255 )

  2015cites this paper
• Effect of Low Cholesterol on Steroid Hormones and Vitamin E Levels: Just a Theory or Real Concern?

  2015cites this paper
• Pregledni Rad Review Article

  year unknowncites this paper
• Vascular Health and Risk Management Dovepress Pcsk9 Inhibition in the Management of Hyperlipidemia: Focus on Evolocumab

  year unknowncites this paper